ProNephro AKI™检测在儿科患者中的多中心性能与稳定性评估
本研究在Roche cobas c501分析仪上评估ProNephroAKI™颗粒增强透射免疫比浊法检测儿科尿液NGAL的分析性能。结果显示空白限、检出限和定量限分别为9、14、18 ng/mL,线性范围50-3000 ng/mL,重复性、批间、日间和总精密度CV分别≤5.0%、≤3.1%、≤1.7%、≤4.9%,三实验室重现性≤6.6%。尿液NGAL在室温稳定2天、冷藏4天、-70°C及以下冻存13个月,可耐受3次冻融循环。
要点
- ProNephroAKI™检测尿液NGAL的空白限、检出限、定量限分别为9、14、18 ng/mL。
- 线性范围50-3000 ng/mL,总精密度CV≤4.9%,三实验室重现性≤6.6%。
- 尿液NGAL室温稳定2天、冷藏4天、-70°C冻存13个月,可耐受3次冻融。
核心结论
- ProNephroAKI™检测具有优良的精密度、重现性、灵敏度、特异性和稳定性,满足危重儿科患者AKI诊断和管理的临床分析性能要求。
研究设计与样本
- 在Roche cobas c501分析仪上运行ProNephroAKI™颗粒增强透射免疫比浊法检测儿科尿液NGAL。
- 评估检测的灵敏度、特异性和线性,在三家实验室用七份儿科尿液样本研究重现性。
- 用十六份天然儿科尿液样本评估室温、冷藏和冷冻储存后尿液NGAL的稳定性。
主要发现
- 空白限、检出限和定量限分别为9、14、18 ng/mL。
- 线性范围确认为50-3000 ng/mL。
- 依照CLSI EP5-03指南,重复性、批间、日间和总精密度CV分别≤5.0%、≤3.1%、≤1.7%、≤4.9%。
- 三实验室重现性≤6.6%。
- 特异性试验显示高比重、15种内源性物质、3种造影剂、pH变化(3.3-10.3)或33种药物化合物无显著干扰,但极高浓度头孢吡肟和头孢曲松除外;10种潜在交叉反应生物标志物未观察到交叉反应。
关键数值与推荐
- 空白限9 ng/mL,检出限14 ng/mL,定量限18 ng/mL。
- 线性范围50-3000 ng/mL。
- 重复性CV≤5.0%,批间CV≤3.1%,日间CV≤1.7%,总精密度CV≤4.9%。
- 三实验室重现性CV≤6.6%。
- 尿液NGAL稳定性:室温2天,冷藏4天,-70°C及以下13个月,3次冻融循环。
临床怎么用
- 该检测可用于危重儿科患者尿液NGAL的定量测定,辅助AKI的早期诊断和管理。
- 需注意极高浓度头孢吡肟和头孢曲松可能干扰检测结果。
- 样本储存条件需遵循验证的稳定性范围:室温2天、冷藏4天、-70°C及以下13个月,避免超过3次冻融。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute Kidney Injury (AKI), defined by increased serum creatinine or decreased urine volume, is highly prevalent in critically ill pediatric patients. Reliance on these for AKI diagnosis is unreliable due to inaccuracy and delayed response. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a promising biomarker for early AKI detection. This study investigated the analytical performance of a new automated urine NGAL test in pediatric patients. MATERIALS AND METHODS: The ProNephroAKI™ particle-enhanced turbidimetric immunoassay was run on the Roche cobas® c501 analyzer to measure urine NGAL in pediatric patients. The test sensitivity, specificity, and linearity were evaluated. The test reproducibility was studied in three laboratories using seven pediatric urine samples. The stability of urine NGAL was assessed in sixteen native urine pediatric samples after storage at room temperature, refrigerated, and frozen. RESULTS: The limits of blank (LoB), detection (LoD), and quantitation (LoQ) were determined as 9, 14, and 18 ng/mL, respectively. Linearity was confirmed across the range of 50-3000 ng/mL. Precision studies following CLSI EP5-03 guidelines showed coefficients of variation (CVs) for repeatability, between-run, between-day, and total precision at ≤5.0 %, ≤3.1 %, ≤1.7 %, and ≤4.9 %, respectively. Reproducibility across three laboratories was ≤6.6 %. Specificity tests showed no significant interference from high specific gravity, 15 endogenous substances, 3 contrast agents, pH variations (3.3-10.3), or 33 pharmaceutical compounds, except very high concentrations of cefepime and ceftriaxone. Cross-reactivity was not observed from 10 potential cross-reactive biomarkers. NGAL stability in urine was tested with samples from 16 patients, demonstrating stability for 2 days at ambient temperature, 4 days refrigerated, 13 months frozen (-70 °C or below), and 3 freeze/thaw cycles. CONCLUSIONS: The ProNephroAKI™ assay shows excellent precision, reproducibility, sensitivity, specificity, and stability, meeting the required analytical performance for clinical use in diagnosing and managing AKI in critically ill pediatric patients.
引用
- Malaeb H, Zilka S, Jarden A, et al. Multicenter evaluation of the ProNephro AKI™ assay performance and stability in pediatric patients. Clin Chim Acta. 2025. PMID: 40713006. doi:10.1016/j.cca.2025.120511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。